Udvalget for Humanmedicinske Lægemidler (CHMP) fandt, at fordelene ved NovoMix til behandling af sukkersyge opvejer risiciene.
The Committee for Medicinal products for Human Use (CHMP) decided that NovoMix’ s benefits are greater than its risks for the treatment of diabetes mellitus.